TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation

Kenichiro Kobayashi, Naoyuki Miyagawa, Kazumasa Mitsui, Masaki Matsuoka, Yasuko Kojima, Hiroyuki Takahashi, Kaori Ootsubo, Junichi Nagai, Hitomi Ueno, Takeshi Ishibashi, Sara Sultana, Yoko Okada, Shingo Akimoto, Hajime Okita, Kimikazu Matsumoto, Hiroaki Goto, Nobutaka Kiyokawa, Akira Ohara

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

We report a 10-year-old male with relapsing Ph-like acute lymphoblastic leukemia (ALL) bearing ATF7IP/PDGFRB translocation. He was refractory to conventional therapy, and was finally treated with single-agent second-generation TKI dasatinib. The therapeutic response was prompt, with the disappearance of minimum residual disease (MRD) based on genomic PCR analysis within 3 months, and he has maintained complete molecular remission for 12 months. This case report describes an early-phase response to TKI monotherapy on Ph-like ALL, and technical tips for MRD monitoring on long-term follow-up.

Original languageEnglish
Pages (from-to)1058-1060
Number of pages3
JournalPediatric Blood and Cancer
Volume62
Issue number6
DOIs
Publication statusPublished - 2015 Jun 1
Externally publishedYes

Fingerprint

Platelet-Derived Growth Factor beta Receptor
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Polymerase Chain Reaction
Therapeutics
Dasatinib

Keywords

  • Genomic PCR
  • MRD
  • PDGFRB fusion
  • Ph-like ALL
  • TKI

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Medicine(all)

Cite this

Kobayashi, K., Miyagawa, N., Mitsui, K., Matsuoka, M., Kojima, Y., Takahashi, H., ... Ohara, A. (2015). TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation. Pediatric Blood and Cancer, 62(6), 1058-1060. https://doi.org/10.1002/pbc.25327

TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation. / Kobayashi, Kenichiro; Miyagawa, Naoyuki; Mitsui, Kazumasa; Matsuoka, Masaki; Kojima, Yasuko; Takahashi, Hiroyuki; Ootsubo, Kaori; Nagai, Junichi; Ueno, Hitomi; Ishibashi, Takeshi; Sultana, Sara; Okada, Yoko; Akimoto, Shingo; Okita, Hajime; Matsumoto, Kimikazu; Goto, Hiroaki; Kiyokawa, Nobutaka; Ohara, Akira.

In: Pediatric Blood and Cancer, Vol. 62, No. 6, 01.06.2015, p. 1058-1060.

Research output: Contribution to journalArticle

Kobayashi, K, Miyagawa, N, Mitsui, K, Matsuoka, M, Kojima, Y, Takahashi, H, Ootsubo, K, Nagai, J, Ueno, H, Ishibashi, T, Sultana, S, Okada, Y, Akimoto, S, Okita, H, Matsumoto, K, Goto, H, Kiyokawa, N & Ohara, A 2015, 'TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation', Pediatric Blood and Cancer, vol. 62, no. 6, pp. 1058-1060. https://doi.org/10.1002/pbc.25327
Kobayashi K, Miyagawa N, Mitsui K, Matsuoka M, Kojima Y, Takahashi H et al. TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation. Pediatric Blood and Cancer. 2015 Jun 1;62(6):1058-1060. https://doi.org/10.1002/pbc.25327
Kobayashi, Kenichiro ; Miyagawa, Naoyuki ; Mitsui, Kazumasa ; Matsuoka, Masaki ; Kojima, Yasuko ; Takahashi, Hiroyuki ; Ootsubo, Kaori ; Nagai, Junichi ; Ueno, Hitomi ; Ishibashi, Takeshi ; Sultana, Sara ; Okada, Yoko ; Akimoto, Shingo ; Okita, Hajime ; Matsumoto, Kimikazu ; Goto, Hiroaki ; Kiyokawa, Nobutaka ; Ohara, Akira. / TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation. In: Pediatric Blood and Cancer. 2015 ; Vol. 62, No. 6. pp. 1058-1060.
@article{5be53b4faec541939592ebb27ddd3bd3,
title = "TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation",
abstract = "We report a 10-year-old male with relapsing Ph-like acute lymphoblastic leukemia (ALL) bearing ATF7IP/PDGFRB translocation. He was refractory to conventional therapy, and was finally treated with single-agent second-generation TKI dasatinib. The therapeutic response was prompt, with the disappearance of minimum residual disease (MRD) based on genomic PCR analysis within 3 months, and he has maintained complete molecular remission for 12 months. This case report describes an early-phase response to TKI monotherapy on Ph-like ALL, and technical tips for MRD monitoring on long-term follow-up.",
keywords = "Genomic PCR, MRD, PDGFRB fusion, Ph-like ALL, TKI",
author = "Kenichiro Kobayashi and Naoyuki Miyagawa and Kazumasa Mitsui and Masaki Matsuoka and Yasuko Kojima and Hiroyuki Takahashi and Kaori Ootsubo and Junichi Nagai and Hitomi Ueno and Takeshi Ishibashi and Sara Sultana and Yoko Okada and Shingo Akimoto and Hajime Okita and Kimikazu Matsumoto and Hiroaki Goto and Nobutaka Kiyokawa and Akira Ohara",
year = "2015",
month = "6",
day = "1",
doi = "10.1002/pbc.25327",
language = "English",
volume = "62",
pages = "1058--1060",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation

AU - Kobayashi, Kenichiro

AU - Miyagawa, Naoyuki

AU - Mitsui, Kazumasa

AU - Matsuoka, Masaki

AU - Kojima, Yasuko

AU - Takahashi, Hiroyuki

AU - Ootsubo, Kaori

AU - Nagai, Junichi

AU - Ueno, Hitomi

AU - Ishibashi, Takeshi

AU - Sultana, Sara

AU - Okada, Yoko

AU - Akimoto, Shingo

AU - Okita, Hajime

AU - Matsumoto, Kimikazu

AU - Goto, Hiroaki

AU - Kiyokawa, Nobutaka

AU - Ohara, Akira

PY - 2015/6/1

Y1 - 2015/6/1

N2 - We report a 10-year-old male with relapsing Ph-like acute lymphoblastic leukemia (ALL) bearing ATF7IP/PDGFRB translocation. He was refractory to conventional therapy, and was finally treated with single-agent second-generation TKI dasatinib. The therapeutic response was prompt, with the disappearance of minimum residual disease (MRD) based on genomic PCR analysis within 3 months, and he has maintained complete molecular remission for 12 months. This case report describes an early-phase response to TKI monotherapy on Ph-like ALL, and technical tips for MRD monitoring on long-term follow-up.

AB - We report a 10-year-old male with relapsing Ph-like acute lymphoblastic leukemia (ALL) bearing ATF7IP/PDGFRB translocation. He was refractory to conventional therapy, and was finally treated with single-agent second-generation TKI dasatinib. The therapeutic response was prompt, with the disappearance of minimum residual disease (MRD) based on genomic PCR analysis within 3 months, and he has maintained complete molecular remission for 12 months. This case report describes an early-phase response to TKI monotherapy on Ph-like ALL, and technical tips for MRD monitoring on long-term follow-up.

KW - Genomic PCR

KW - MRD

KW - PDGFRB fusion

KW - Ph-like ALL

KW - TKI

UR - http://www.scopus.com/inward/record.url?scp=84927911280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927911280&partnerID=8YFLogxK

U2 - 10.1002/pbc.25327

DO - 10.1002/pbc.25327

M3 - Article

C2 - 25400122

AN - SCOPUS:84927911280

VL - 62

SP - 1058

EP - 1060

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 6

ER -